Leukotriene modifiers for asthma treatment
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Leukotrienes (LTs), including cysteinyl LTs (CysLTs) and LTB 4, are potent lipid mediators that have a role in the pathophysiology of asthma. At least two receptor subtypes for CysLTs, CysLT 1 and CysLT 2, have been identified. The activation of the CysLT 1 receptor is responsible for most of the pathophysiological effects of CysLTs in asthma, including increased airway smooth muscle activity, microvascular permeability, and airway mucus secretion. LTB 4 might have a role in severe asthma, asthma exacerbations, and the development of airway hyperresponsiveness. CysLT 1 receptor antagonists can be given orally as monotherapy in patients with mild persistent asthma, but these drugs are generally less effective than inhaled glucocorticoids. Combination of CysLT 1 receptor antagonists and inhaled glucocorticoids in patients with more severe asthma may improve asthma control and enable the dose of inhaled glucocorticoids to be reduced while maintaining similar efficacy. The identification of subgroups of asthmatic patients who respond to CysLT 1 receptor antagonists is relevant for asthma management as the response to these drugs is variable. CysLT 1 receptor antagonists have a potential anti‐remodelling effect that might be important for preventing or reversing airway structural changes in patients with asthma. This review discusses the role of LTs in asthma and the role of LT modifiers in asthma treatment. Cite this as: P. Montuschi and M. L. Peters‐Golden, Clinical & Experimental Allergy, 2010 (40) 1732–1741.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exhaled breath condensate: methodological recommendations and unresolved questions
Horváth, I., Hunt, J., & Barnes, P. J. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00029705 · Cited by 1,284
Narala, V. R., Adapala, R. K., Suresh, M. V., Brock, T. G., Peters-Golden, M., & Reddy, R. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.085118 · Cited by 126
Cited by
Cole, S. P. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.609248 · Cited by 361
Beneficial effects of n-3 PUFA on chronic airway inflammatory diseases
Giudetti, A. M., & Cagnazzo, R. (2012) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2012.09.006 · Cited by 109
Lipid mediators and allergic diseases
Fanning, L. B., & Boyce, J. A. (2013) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2013.06.031 · Cited by 70
Advance in Managing Indoor Cat Allergen Proteins: Molecular Insights, Detection, and Control
Jiang, Y., Tian, X., Fu, X., Ma, B., Wang, Z., Han, B., Tao, H., Wang, J., & Wang, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210913 · Cited by 3
“Furthermore, leukotriene receptor antagonists (e.g., montelukast [155,156]) provide an alternative oral maintenance option by inhibiting inflammatory mediators derived from arachidonic acid metabolism [157,158].”
Metadata
- Authors
- Montuschi, P., & Peters‐Golden, M. L.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2010-11-09
- Volume
- 40
- Issue
- 12
- Pages
- 1732-1741
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W1926255205
- Cited by
- 112
- References
- 2
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leukotriene modifiers for asthma treatment. https://app.cochat.ai/papers/10.1111/j.1365-2222.2010.03630.x
- The paper
- Montuschi, P., & Peters‐Golden, M. L. (2010). Leukotriene modifiers for asthma treatment. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2010.03630.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.